

Contents Volume 2

No. 1

Risk and safety in radiography in women of childbearing ability <i>R.H. Pearson (U.K.)</i>	1
Ethics in the pharmaceutical industry: acceptance of responsibility or a facet of marketing? <i>P. Chirac (France)</i>	7
Concomitant drug use among patients on cardiac glycosides <i>H.G. Leufkens, R.M.C. Herings, W.J. Kollöffel and A. Bakker (The Netherlands)</i>	11
Prevention of adverse reactions to intravascular contrast media <i>P. Soyer, M. Levesque and P. Rouleau (France)</i>	21
Drugs after 1992; an equation with many remaining unknowns <i>E.J. Boer (The Netherlands)</i>	29
Detecting adverse drug reactions – a concise update. I. Cohort and case control studies <i>D.H. Lawson (U.K.)</i>	39
Detecting adverse drug reactions – a concise update. II. Monitored release <i>R.D. Mann (U.K.)</i>	45
Detecting adverse drug reactions – a concise update. III. The record-linkage system: a duality of purpose <i>M.L. Morse (U.S.A.)</i>	51
Reviews of books and studies	57
Forthcoming Meetings	59
Announcement from the Publisher	60
Information for Authors	61

Nos. 2, 3

Risk management: a practical approach	63
The physician's civil liability under Danish law <i>N. Fenger and M. Broberg (Denmark)</i>	65

What is risk management? <i>G. Hill (U.K.)</i>	83
Is risk management necessary? <i>R. Dingwall and P. Fenn (U.K.)</i>	91
Risk management in trauma and orthopaedics <i>R. Vickers (U.K.)</i>	107
Risk management in anaesthesia <i>A.R. Aitkenhead (U.K.)</i>	113
Risk management in surgery <i>J.C. Smith (U.K.)</i>	125
The risks of obstetrics and gynaecology in practice <i>G. Chamberlain (U.K.)</i>	129
Risk management in obstetrics and gynaecology <i>C.E. James (U.K.)</i>	133
Risk management implementation programmes <i>G. Roberts (U.K.)</i>	141

Regular Papers

Extra-hospital dialysis: the patient is at risk, not the method <i>B. Viron and F. Mignon (France)</i>	145
Electrical safety in patient care areas <i>R. Cislo and B. Rasaiah (Canada)</i>	157
Meeting Report: Health foods or healthy foods	161
Reviews of books and studies	165
Information for Authors	169

No. 4

Classifying improvements to drug marketing and justifications for claims of efficacy <i>P.R. Mansfield (Australia)</i>	171
Adverse drug reactions: scope and limitations of causality assessment and the use of algorithms <i>W. Castle (U.K.)</i>	185
Editorial Note: Care and cholesterol <i>G. Dukes</i>	193

	365
The long-term safety of antihyperlipidaemic drugs <i>O.R. Ødegaard (Norway)</i>	197
Monitoring the long-term safety of lipid lowering therapy <i>J.F. Walker (U.S.A.)</i>	203
Problems and possibilities of spontaneous adverse reaction reporting systems <i>K.H. Kimbel (Germany)</i>	209
Registration of post-operative wound infections: a method for reducing the rate of infections <i>N. Darle, A. Falk, M. Hall-Angerås and H. Thunberg-Sjöström (Sweden)</i>	219
Hippocrates	225
Reviews of books and studies	229
Forthcoming Meetings	233
Information for Authors	235

No. 5

The International Clearinghouse for Birth Defects Monitoring Systems

Editorial: Monitoring birth defects	237
The International Clearinghouse for Birth Defects Monitoring Systems: Past, present and future <i>J.D. Erickson (U.S.A.)</i>	239
What does it mean to be a member of the Clearinghouse? <i>E. Robert and M.L. Martínez-Frías (France, Spain)</i>	249
An ICBDMS collaborative study: monitoring multimalformed infants <i>P. Mastroiacovo (Italy)</i>	255
Birth defects monitoring in underdeveloped countries: an example from Uruguay <i>E.E. Castilla, J.S. Lopez-Camelo, G.P. Dutra and J.E. Paz (Brazil, Argentina)</i>	271
Statistical methods for surveillance of congenital malformations: when do the data indicate a true shift in the risk that an infant is affected by some type of malformation? <i>R.T. Lie, S.E. Vollset, B. Botting and R. Skjærven (Norway, U.K.)</i>	289
Information for Authors	301

No. 6

Editorial	303
Fatal adverse drug reactions reported in Denmark 1968–1988 <i>H. Kromann-Andersen, M. Andersen, H.O. Andersen and P. Juul (Denmark)</i>	305
Risk evaluation and estrogens <i>I. Palmlund (U.S.A.)</i>	321
Risk, estrogens – and a poem	343
An international survey on drug utilization during pregnancy. Collaborative Group on Drug Use in Pregnancy (CGDUP)	345
Law Notes	351
Hippocrates	355
Reviews of books and studies	359
Contents Volume 2	363